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ABSTRACT 
Background: Ehrlich-Lettre ascites carcinoma (EAC) is also known as Ehrlich cell. It was originally established as 
an ascites tumor in mice. The current concept that cytotoxic chemotherapeutic agents are administered at a dose to 
the maximum a patient can tolerate before the onset of severe and even life-threatening toxicity is still in wide 
clinical use. This study was conducted to evaluate the response of chemotherapy in the treatment of Ehrlich’s ascetic 
carcinoma. The various parameters to assess the response of various therapeutic schedules were regression of tumor 
by decrease in body weight of mice and decrease in abdominal girth; cell count of ascetic fluid and morphological 
changes of tumor cells after treatment with drugs and to study the percentage viability of the cells. Materials & 
Methods: A mouse bearing the tumor strain was taken from our laboratory in the Department of Pathology, 
IPGMER, Kolkata, where the strain was being maintained serially by inoculation of malignant cells into healthy 
mice every 8-10 days. In our work altogether 25 mice were taken for each set of experimental work. They were 
divided in four groups of 5-10 mice in each group. Results: All the mice in Group III revealed extensive metastasis 
with haemorrhagic ascetic fluid. About 60% mice of Group IV showed metastatic but there was no haemorrhagic 
fluid. None of the mice of Group IV survived beyond 35 days. Group III mice survived for a maximum of 25 days. 
Most of them died between 2-24 days. Conclusion: With the chemotherapy there was reduced cell count and cell 
viability. Actinomycin D alone produced a moderate effect on tumor cells. 
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INTRODUCTION 
Cancers are caused by mutations that may be inherited, 
induced by environmental factors, or result from DNA 
replication errors.[1] 
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Aging is the main risk factor for carcinogenesis in 
multicellular animal organisms including humans.[2] 
Cancer is ranked as the first or second leading cause of 
death in 91 of 172 countries and is third or fourth in an 
additional 22 countries. [3] Cancer is the second and 
fourth leading cause of adult death in urban and rural 
India, respectively. Cancer is now the leading cause of 
catastrophic health spending, distress financing, and 
increasing expenditure before death in India. [4,5]In the 
early 1900s, the famous German chemist Paul Ehrlich 
set about developing drugs to treat infectious diseases. 
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He was the one who coined the term “chemotherapy” 
and defined it as the use of chemicals to treat disease. 
He was also the first person to document the 
effectiveness of animal models to screen a series of 
chemicals for their potential activity against diseases, 
an accomplishment that had major ramifications for 
cancer drug development. In 1908, his use of the rabbit 
model for syphilis led to the development of arsenicals 
to treat this disease. Ehrlich was also interested in 
drugs to treat cancer, including aniline dyes and the 
first primitive alkylating agents, but apparently was not 
optimistic about the chance for success.[6] For most 
primary tumors the treatment of choice is surgery and 
radiotherapy, which measures can be very effective for 
controlling localized tumors and indeed surgery and 
radiotherapy dominated the field of cancer therapy into 
the 1960s. However, at the time of diagnosis the 
majority of cancers have already microscopically 
metastasized throughout the body, leading to recurrent 
disease in the majority of cancer patients. In view of 
this, systemic chemotherapy is required to control 
outgrow of metastases. Although for some invasive 
tumors at advanced disease stages, chemotherapy 
might be administered up front to allow better surgery, 
in essence presently the chemotherapy of cancer is the 
treatment of metastases, either known or assumed, 
except for hematological malignancies. The current 
concept that cytotoxic chemotherapeutic agents are 
administered at a dose to the maximum a patient can 
tolerate before the onset of severe and even life-
threatening toxicity is still in wide clinical use.[7] 
OBJECTIVES 
This study was conducted to evaluate the response of 
chemotherapy in the treatment of Ehrlich’s ascetic 
carcinoma. The various parameters to assess the 
response of various therapeutic schedules were as 
follows:  
1. To assess the regression of tumor by decrease in 
body weight of mice and decrease in abdominal 
girth 
2. To study the cell count of ascetic fluid after 
treatment with drugs 
3. To study morphological changes of tumor cells 
after subjecting it to antineoplastic drug 
4. To study the percentage viability of the cells  
5. To study the animal survival  
MATERIALS & METHODS 
Transplantation of Ehrlich’s ascetic carcinoma in mice 
(ascetic form): the proliferation of malignant cells of 
the Ehrlich’s ascetic carcinoma strain simulates the 
biology of any neoplasis. Hence this study forms a 
tumor model on which different antineoplastic agents 
have been tried to study the kind of therapy which 
would form the best mode of treatment. The different 
antineoplastic regimen that have been undertaken in 
our study were effects on Ehrlich’s ascetic carcinoma 
(EAC) in mice when treated with actinomycin D; 
mitomycin C and actinomycin D and effects of EAC 
with radiotherapy alone.  
Tumor strain 
 A mouse bearing the tumor strain was taken from our 
laboratory in the Department of Pathology, IPGMER, 
Kolkata, where the strain was being maintained serially 
by inoculation of malignant cells into healthy mice 
every 8-10 days. The mouse that was taken had a huge 
ascites from which cells were taken to inoculate mice 
further. Male Swiss A albino mice weighing about 16-
18 grams were chosen for our study.  
Transplantation 
 At first a preliminary diagnosis was made regarding 
the presence of ascites in the mice by noting the gain in 
weight; gain in abdominal girth and by palpating the 
abdomen. Then with the help of a sterile tuberculin 
syringe and a needle of 21 guage, 0.5 ml sterile normal 
saline was taken and peritoneal cavity was punctured. 
This 0.5 l sterile normal saline was then pushed into the 
peritoneal cavity to dilute the cell suspension in the 
immediate vicinity of the needle and to separate any 
fibrin coagulum if formed, so that the cell suspension 
could flow out freely. Sample with whitish fluid was 
taken in the syringe. This was then diluted 1:10 in 
sterile physiological saline.  A drop from this 
suspension was taken and changed in the Neubauer’s 
haemocytometer. A cell count was done under the 
optical microscope. The cell suspension was again 
diluted in sterile normal saline to obtain a desired cell 
suspension of about 107 cells/ml. Simultaneously 0.02 
ml cell suspension was taken, diluted in the ratio of 
1:10 in 0.15% trypan blue made up in physiological 
saline. A drop of cell suspension was taken and a 
coverslip preparation was made to study the viability of 
the cells. The viable cells did not take up any stain 
whereas the dead cells were stained blue. Percentage of 
viable cells was noted down. The slides made out from 
smears of centrifuged deposit were stained by 
haemotoxylin and eosine which showed large 
malignant cells with hyperchromatic nuclei with 
nucleoli and scanty cytoplasm [Fig. 2]. After having 
confirmed the presence of malignant cells, the 
suspension was used to inoculate the mice. About 
0.1ml of prepared suspension was then taken and 
diluted in 0.4 ml of sterile normal saline and this 
mixture (0.5 ml) was inoculated into each mouse 
intraperitoneally. Thus the desired cell concentration of 
106 cells per inoculums dose was obtained. The mice 
were maintained on pellets prepared by Hindustan 
Lever Company and water ad libitum. The weight of 
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individual mice with their abdominal girth was noted 
before starting the experiment.  
Animal grouping 
 In our work altogether 25 mice [Fig. 1] were taken for 
each set of experimental work. They were divided in 
four groups of 5-10 mice in each group. The group 
distribution was as follows. 
Group I: Healthy mice which were maintained on feed 
and water only. These served as healthy controls. 
Group II: Mice who were given only therapy without 
any preceding malignant cell inoculation.  
Group III: Mice who were inoculated with the tumor 
cells and left as such without any treatment. These 
served as tumor controls [Fig. 3]. 
Group IV: Mice who were given therapy on the tumor 
they were bearing.  
Methods of observations 
 Each mouse was weighed in gms before 
transplantation of tumor strain; before starting 
treatment and 5 days after the end of treatment. 
Abdominal girth of each mouse was taken in cms in the 
same schedule as above. The effect of therapy was 
recorded according to the protocol laid by Sugiura K 
(1961). [8] 
 [+++]  Indicates complete inhibition or diminution of 
ascites 
[++] Marked inhibition indicating no abdominal 
distension, no gross ascites 
[+] Moderate inhibition indicating slight distension; the 
fluid volume increased only upto ¼ of the volume 
increased only upto ¼ of the volume of the tumor 
control 
[±] Slight inhibition indicating moderate abdominal 
distension, the fluid volume increased upto ½ of the 
volume of the tumor control  
[-] No effect, indicating marked abdominal distension, 
the fluid volume increased upto ¾ or more of the 
volume of the tumor control. Survival time of each 
mouse was noted in relation to the life of healthy and 
drug control mice.  In case of any death of any mouse a 
post-mortem was carried out to find out the cause of 
death. Tissues from lung, liver and kidneys were taken 
and were fixed in 10% formalin solution. Tissues were 
processed as usual and paraffin sections were made and 
stained with haematoxylin and eosine. Each set of 
experiment was done twice.  
Experiment 
 About 25 male Swiss albino mice aged around 4-6 
weeks were taken and their individual weight and 
abdominal girth measured. Of them 15 were inoculated 
with the tumor cells intraperitoneally by aseptic means. 
The individual inoculus dose was 106 cells 
approximately. The mice were divided into 4 groups.  
Group I: 5 Healthy control mice 
Group II: 5 drug control mice. These healthy non-
tumor bearing mice were given the drug actinomycin D 
in the therapeutic concentration of 2 mcg. 
Group III: Tumor control mice- these 5 mice were 
inoculated with Ehrlich’s ascetic carcinoma cells. They 
were kept untreated.  
Group IV: Treatment group: 10 mice. These tumor 
bearing mice which had been inoculated with Ehrlich’s 
ascetic carcinoma cells were subjected to treatment 
with actinomycin D in its therapeutic concentration.  
Confirmation of Successful Transplantation   
After about 5-7 days of inoculation any gain in weight 
and abdominal girth was noted. By careful palpation it 
was seen that the abdomen showed evidence of fluid 
collection. A peritoneal tap was done carefully in an 
aseptic manner and the fluid obtained from the 
peritoneum was simultaneously diluted in normal 
saline to give a 1:20 dilution. This fluid was seen under 
the optical microscope in a Neubauer chamber. A cell 
count was done and recorded. A centrifuged deposit of 
the cell suspension was taken and stained with 
Haematoxylin and eosin [Fig. 2]. The presence of large 
cells with hyperchormatic nuclei, nucleoli and a thin 
rim of basophilic cytoplasm confirmed the presence of 
malignant cells in the peritoneal fluid. Immediately a 
viable count was done and it was seen that about 90-
95% cells were viable. Now a treatment schedule was 
adapted. Actinomycin D was obtained from Sigma 
chemical compound contained 5 mg in a sealed vial. It 
was diluted in sterile distilled water to give a 
concentration of 2 mcg in 0.2 ml distilled water. The 
period of treatment was 10 days. Actinomycin D was 
injected intraperitoneally carefully so that there was no 
spillage of actinomycin D on the peritoneum. Only 
after confirming that it was in the cavity which was 
done by first withdrawing some fluid from the cavity, 
only than the drug was pushed in. Thus the total dose 
that was given was 20 mcg per mouse.  
RESULTS 
Table 1: Effect of actinomycin D on Ehrlich’s ascetic carcinoma in mice 
Groups Before therapy: after 7 days of tumor cell inoculation After therapy: 5 days after cessation of therapy 
 Avg. Wt. 
Of mice 
(gms.) 
Avg. 
Abdom. 
Girth (cm) 
Avg. Cell 
count 
(per 
cmm) 
Cell 
surviving 
after 2 hr 
(%) 
Avg. Wt. 
of mice 
(gm) 
Avg. 
Abdom. 
Girth 
(cm) 
Avg. Cell 
count 
(per 
cmm) 
Cell 
surviving 
after 2 hr 
(%) 
I 19 6.3 Nil - 20 6.5 Nil - 
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II 
III 
IV 
18 
24 
24 
6 
7.5 
7.6 
Nil 
4 x 105 
4 x 105 
- 
85 
85 
17.5 
32 
27 
5.8 
13.3 
9.6 
Nil 
9 x 108 
5 x 105 
- 
75 
55 
 
 All the healthy mice gained in weight and abdominal 
girth. The drug control mice lost some weight. After 
the treatment, morphological features of aspirated cells 
in smear stained in haematoxylin and eosine showed 
the following features: degeneration of cells marked by 
vacuolation of cytoplasm; there is diminiution in size 
of the nucleus and the nuclear cytoplasmic ratio had 
diminished [Figure. 4 & 5].  
Those mice which died, a post mortem was carried out 
to find the cause of death. All the mice in Group III 
revealed extensive metastasis with haemorrhagic 
ascetic fluid. About 60% mice of Group IV showed 
metastatic but there was no haemorrhagic fluid. None 
of the mice of Group IV survived beyond 35 days. 
Group III mice survived for a maximum of 25 days. 
Most of them died between 2-24 days. Therefore we 
can see that healthy mice gained in weight and 
abdominal girth whereas mice of Group II i.e. which 
served as drug treatment control lost weight as well as 
there was reduction of abdominal girth. There was a 
partial reduction in the malignant cell count of them 
mice in Group IV. None of the mice showed complete 
absence of malignant cells from the peritoneal fluid. 
All mice of Group III died within 20-25 days of 
inoculation. A complete cure could not be achieved by 
this drug schedule, which probably could have been 
achieved by increasing the dose of the drug.  
 
Figure 1: Two mice, one healthy on the right and another ascetic tumor bearing mice on the left. 
Their age and abdominal girth were nearly similar before tumor inoculation 
 
Figure 2: A haematoxylin and eosine stained smear of centrifuged deposit of peritoneal fluid. Large cells with 
hyperchromatic nuclei with a very thin rim of basophilic cytoplasm (x 400) 
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Figure 3: Confirmation of a successful tumor uptake in the peritoneum before treatment with actinomycin D 
(X 160) 
 
Figure  4: Morphology of cells after treatment with actinomycin D. Cells showed alterations in 
nuclear:cytoplasmic ratio, vacuolation of the cytoplasm, and nuclear vacuolation (x 400) 
 
Figure 5: A viability of cells after 2 hrs of incubation showed increased number of nonviable cells as 
compared to control after treatment with actinomycin D (x 160) 
DISCUSSION 
Ehrlich-Lettre ascites carcinoma (EAC) is also known 
as Ehrlich cell. It was originally established as 
an ascites tumor in mice. The tumor was cultured in 
vivo, which became known as the Ehrlich cell. After 
1948 Ehrlich cultures spread around research institutes 
all over the world. The Ehrlich cell became popular 
because it could be expanded by in vivo passage. This 
made it useful for biochemical studies involving large 
amounts of tissues. It could also be maintained in 
vitro for more carefully controlled studies. Culture 
techniques in large-scale, mice passage are less 
attractive, due to the contamination of the tumor with  
 
multifarious host inflammatory cells. EAC is referred 
to as undifferentiated carcinoma, and is originally 
 hyper-diploid. The permeability to water is highest at 
the initiation of the S phase and progressively 
decreases to its lowest value just after mitosis. 
Activation heats for water permeability vary during the 
cell cycle, ranging from 9–14 kcal/mole.[9]  
Actinomycin D is a well-known antibiotic of the 
actinomycin group that exhibits high antibacterial 
and antitumor activity. Actinomycin D has been widely 
used in clinical practice since 1954 as an anticancer 
drug for treating many tumors and it is also a useful 
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tool in biochemistry and molecular biology. There are 
several mechanisms of its action that are responsible 
for its cytotoxic and antitumor action, these being 
associated with DNA functionality, leading to RNA 
and, consequently, protein synthesis inhibition. The 
two main mechanisms are intercalation to DNA and the 
stabilization of cleavable complexes of topoisomerases 
I and II with DNA, in which a phenoxazone ring 
localizes between GpC base pair sequence in DNA and 
polypeptide lactones rings occupy a position in the 
minor groove of the DNA helix or the drug penetrates 
to a place in the DNA structure where topoisomerase 
binds with DNA, respectively. Moreover, the slow 
dissociation of actinomycin D from DNA complexes, 
its photodynamic activity and free radical formation, as 
well as other biochemical effects of activity of 
actinomycin D may be, as suggested, important factors 
that influence the biological activity of this drug.[10] 
 
CONCLUSION 
 
With the chemotherapy there was reduced cell count 
and cell viability. Actinomycin D alone produced a 
moderate effect on tumor cells. We can see that healthy 
mice gained in weight and abdominal girth whereas 
mice of Group II i.e. which served as drug treatment 
control lost weight as well as there was reduction of 
abdominal girth. There was a partial reduction in the 
malignant cell count of them mice in Group IV. None 
of the mice showed complete absence of malignant 
cells from the peritoneal fluid. All mice of Group III 
died within 20-25 days of inoculation. A complete cure 
could not be achieved by this drug schedule, which 
probably could have been achieved by increasing the 
dose of the drug. EAC has a resemblance with human 
tumors which are  the most sensitive to chemotherapy 
due to the fact that it is undifferentiated and that it has a 
rapid growth rate.  
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